For long-term investors, finding quality Australian stocks that can grow their earnings year after year is the ultimate goal.
These are the kinds of businesses you can buy, tuck away, and confidently hold through market ups and downs.
They are not about chasing quick gains, they are about owning structural growth stories with enduring demand, proven execution, and management teams that think in decades, not quarters.
With that in mind, here are two ASX growth stocks that analysts think could be great long-term picks:
Image source: Getty Images
NextDC Ltd (ASX: NXT)
NextDC sits at the heart of Australia's digital infrastructure. It designs, builds, and operates state-of-the-art data centres that power everything from cloud computing to artificial intelligence. Every time you do something on your phone or computer, there's a strong probability that it is relying on the kind of high-performance facilities NextDC provides.
As the global economy becomes increasingly data-driven, demand for secure, energy-efficient, and scalable data centres is only set to rise. NextDC's client base already includes some of the world's biggest technology players, and the company is now expanding internationally.
Data centre contracts are long-term, often locked in for years, and underpinned by essential digital infrastructure. This creates recurring revenue and high visibility for investors. And with the digital transformation still in its early days, NextDC looks like a business built to grow for decades.
Macquarie is a big fan of the company and has an outperform rating and $20.90 price target on its shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another Australian growth stock that could be a top long term buy is Telix Pharmaceuticals. It is arguably one of the most exciting healthcare growth stories on the ASX.
This biotechnology stock specialises in molecular imaging and targeted radiation therapies. This is a new frontier in cancer diagnosis and treatment that combines precision medicine with powerful therapeutic technology.
Its flagship product, Illuccix, is already approved and generating strong sales in the US for prostate cancer imaging. The company is also advancing a deep pipeline of new radiopharmaceutical candidates targeting kidney, brain, and other cancers. Each of these has the potential to open multi-billion-dollar global markets.
And while it had a few setbacks with the US FDA this year, analysts appear to believe this is only temporary and remains positive on the long term.
One of those is Bell Potter, which has a buy rating and $23.00 price target on its shares.
